Koers Asarina Pharma AB (publ) Nasdaq Stockholm
Aandelen
SE0011641794
Biotechnologie & Medisch Onderzoek
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 21,03 mln. 221 mln. 19,65 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -31 mln. -326 mln. -28,97 mln. | Nettowinst (verlies) 2022 | -13 mln. -137 mln. -12,15 mln. | EV/omzet 2021 | - |
Nettoliquiditeiten 2021 | 16,42 mln. 172 mln. 15,34 mln. | Nettoliquiditeiten 2022 | 13,58 mln. 143 mln. 12,69 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-1,15
x | K/w-verhouding 2022 |
-1,31
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 57,98% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Peter Nordkild
CEO | Chief Executive Officer | 69 | 01-01-16 |
Director of Finance/CFO | 69 | 01-04-17 | |
Public Communications Contact | 63 | 01-01-11 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul de Potocki
CHM | Chairman | 62 | 01-01-18 |
Public Communications Contact | 63 | 01-01-11 | |
Marianne Kock
BRD | Director/Board Member | 69 | 01-01-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,15% | 124 mld. | |
+18,02% | 111 mld. | |
-12,75% | 23,17 mld. | |
+5,07% | 22,94 mld. | |
-39,94% | 17,42 mld. | |
-9,86% | 17,42 mld. | |
-14,97% | 16,9 mld. | |
+2,80% | 13,71 mld. | |
+27,39% | 11,82 mld. |